Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.prnil.2016.05.001 http://scihub22266oqcxt.onion/10.1016/j.prnil.2016.05.001 C4916061!4916061 !27358841     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27358841 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Prostate+Int 2016 ; 4 (2 ): 37-42 Nephropedia Template TP {{tp|p=27358841 |t=2016. New drugs in prostate cancer |pdf=|usr=}}{{27358841 }} gab.com Text New drugs in prostate cancer JO: Prostate Int http://www.kidney.de/pget.php?&tw=1&pmid=27358841 #FOAvip The standard primary treatment for advanced prostate cancer has been hormonal therapy since the 1940s. However, prostate cancer inevitably progresses to castration-resistant prostate cancer (CRPC) after a median duration of 18 months of androgen deprivation therapy. In patients with CRPC, docetaxel has been regarded as the standard treatment. However, survival advantages of docetaxel over other treatments are slim, and the need for new agents persists. In recent years, novel agents, including abiraterone, enzalutamide, cabazitaxel, radium-223, and sipuleucel-T, have been approved for the treatment of CRPC, and more such agents based on diverse mechanisms are under investigation or evaluation. In this article, the authors reviewed the current literature on recent advances in medical treatment of prostate cancer, especially CRPC. In addition, the authors elaborated on novel drugs for prostate cancer currently undergoing investigation and their mechanisms. Twit Text FOAVip New drugs in prostate cancer ????Prostate Int http://www.kidney.de/pget.php?&tw=1&pmid=27358841 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27358841 #FOAvip English Wikipedia <ref>{{Cite pmid|27358841 }}</ref> New drugs in prostate cancer #MMPMID27358841 Yoo S ; Choi SY ; You D ; Kim CS Prostate Int 2016[Jun]; 4 (2 ): 37-42 PMID27358841 show ga The standard primary treatment for advanced prostate cancer has been hormonal therapy since the 1940s. However, prostate cancer inevitably progresses to castration-resistant prostate cancer (CRPC) after a median duration of 18 months of androgen deprivation therapy. In patients with CRPC, docetaxel has been regarded as the standard treatment. However, survival advantages of docetaxel over other treatments are slim, and the need for new agents persists. In recent years, novel agents, including abiraterone, enzalutamide, cabazitaxel, radium-223, and sipuleucel-T, have been approved for the treatment of CRPC, and more such agents based on diverse mechanisms are under investigation or evaluation. In this article, the authors reviewed the current literature on recent advances in medical treatment of prostate cancer, especially CRPC. In addition, the authors elaborated on novel drugs for prostate cancer currently undergoing investigation and their mechanisms. äNew drugs in prostate cancer (epmc).pdf DeepDyve Pubget Overpricing